The US FDA has recently granted approval for the marketing and use of a new bio-marker test for ovarian cancer. The combination of tests examining levels of HE4 and CA125 with the Risk of Ovarian Malignancy Algorithm (ROMA~(TM)), developed at the Women and Infants Hospital of Rhode Island (Providence, RI, USA), promises high accuracy and specificity when determining the risk of ovarian cancer in both pre- and postmenopausal women. The new tool may help overcome issues such as distinguishing between benign and malignant pelvic mass and identifying individuals with a high likelihood of malignancy who would benefit from surgery.
展开▼
